Krystal Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the annual meeting of stockholders held on May 31, 2018. Krystal Biotech, Inc. is a Delaware corporation and an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes or operational updates are disclosed in this filing. The document details the outcomes of two specific shareholder votes.
Management Commentary and Voting Results
Two matters were submitted to a vote of security holders:
- Election of Class I Directors: Two directors were elected for a term expiring at the 2021 annual meeting.
- Ratification of Auditors: Shareholders ratified the selection of Mayer Hoffman McCann P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
| Director Candidate | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Suma M. Krishnan | 4,751,588 | 493,865 | 1,066,704 |
| R. Douglas Norby | 4,750,088 | 493,365 | 1,066,704 |
| Proposal | Votes For | Votes Against | Abstentions |
|---|---|---|---|
| Ratification of Auditor | 6,310,833 | 224 | 1,100 |
Key Facts for Investor Verification
- Both Class I director candidates received majority support with over 4.75 million votes each.
- The ratification of the independent auditor passed overwhelmingly with 6.31 million votes for and only 224 against.
- Approximately 1.06 million shares were subject to broker non-votes regarding the director elections.
- The company is classified as an emerging growth company.